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(PCV2) generate antibody responses capable to
neutralise PCV2 isolates of different genotypes
and geographic origins
Sherry Kurtz1,2, Llorenç Grau-Roma1,3,4, Martí Cortey1,5, Maria Fort1,6, Fernando Rodríguez1, Marina Sibila1
and Joaquim Segalés1,3*Abstract
Porcine circovirus type 2 (PCV2) is the essential infectious agent for PCV2-systemic disease (PCV2-SD, formerly known as
postweaning multisystemic wasting syndrome) and other pathological conditions. Recent studies indicated antigenic
variability amongst different PCV2 isolates and suggested that single amino acid changes within the capsid protein
determine differences in the level of neutralization by specific monoclonal antibodies. The objective of the present
study was to examine the cross-reactivity of PCV2 antibodies induced in the context of a natural infection against
different PCV2 isolates belonging to genotypes PCV2a and PCV2b. Sera taken from several farms from animals of
varying health status (PCV2-SD and age-matched healthy pigs and a set of slaughter-aged animals) were assayed for
neutralizing activity against four PCV2 isolates from both predominant genotypes (PCV2a and PCV2b) and of differing
geographic origins (Europe and North-America). Results showed that most of studied pigs (79 out of 82) contained
neutralizing antibodies (NA) able to neutralize all four studied viral strains. Overall, pigs had significantly higher NA titres
against PCV2a than against PCV2b (P < 0.001). Accordingly, studied serums were able to better neutralize Burgos390L4
and Stoon-1010 strains (PCV2a) than L-33-Sp-10-54 and MO/S-06 strains (PCV2b) (P < 0.001). No differences between
capabilities of seroneutralization of viruses from different geographic origin were observed. Present data suggests that
sequence differences between PCV2 isolates translate to functional antigenic differences in viral neutralization in vivo.Introduction
Porcine circoviruses (PCV) are small non-enveloped,
single-stranded DNA viruses within the Circoviridae family.
Within this family, there are two types of PCV, PCV type 1
(PCV1) and PCV type 2 (PCV2). PCV1 was firstly identi-
fied as a non-cytopathic contaminant of the porcine kidney
cell line PK-15, but it does not apparently cause disease in
swine [1,2]. PCV2 is the essential etiological agent of
PCV2-systemic disease (PCV2-SD, formerly known as post-
weaning multi-systemic wasting disease, PMWS), as well as
other porcine circovirus diseases (PCVD) [3-5]. Although
firstly described in North America in 1991, PCV2-SD and* Correspondence: joaquim.segales@cresa.uab.cat
1Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la
Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
3Departament de Sanitat i Anatomia Animals, Universitat Autònoma de
Barcelona, 08193 Bellaterra, Barcelona, Spain
Full list of author information is available at the end of the article
© 2014 Kurtz et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.PCV2 are now found in almost every pig-producing coun-
try in the world [6-8]. Animals suffering from PCV2-SD
demonstrate clinical signs of wasting or decreased weight
gain, as well as anaemia, diarrhoea and/or respiratory dis-
tress [7]. Due to increased mortality rates and the impact
on weight gain, PCV2-SD has a serious economic impact
on the swine production industry.
The PCV2 genome is typically 1767–1768 nucleotides
in length and encodes three open reading frames (ORF):
ORF1, which encodes the replicase proteins (rep and rep’),
essential for viral replication; ORF2, encoding the capsid
(Cap) protein, the structural protein of the virus; and
ORF3, a protein that is not essential for viral replication,
but might play a role in virulence [9-11]. PCV2 isolates
can be classified phylogenetically into four genotypes,
PCV2a, PCV2b, PCV2c and PCV2d [12], being the
first one especially prevalent before the major outbreaks ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lent during and after major PCV2-SD epizootics as well as
nowadays [12-17]. PCV2a and PCV2b show a relatively
high level of nucleotide identity in the rep (97-100%) and
cap genes (91-100%), and also high similarity at the amino
acid level, where identity is 97-100% for Rep and 89-100%
for Cap [18]. However, what the biologically relevant differ-
ences are between the phylogenetic groups and how those
differences may impact virulence is still being determined.
In general, protective immunity against PCV2 is thought
to depend on a strong humoral immune response [19-22],
while little is known about the contribution of cell medi-
ated immunity [23,24]. A protective humoral response is,
in part, reliant on the production of neutralizing anti-
bodies (NA) against the virus [20,21]. Several groups have
undertaken studies to elucidate the immunorelevant epi-
topes within the viral proteins, particularly Cap [25-28].
These studies mapped several epitopes throughout the
Cap protein, suggesting that the Cap itself is a major target
of immune recognition, a fact that has been exploited in
the production of several of the commercially licensed
PCV2 vaccines [22,29]. Moreover, several groups have de-
scribed monoclonal antibodies with neutralizing activity
against PCV2 Cap, and have used these to map the dom-
inant immunological epitopes important for neutralization
within PCV1 and PCV2 Cap [26,27,30,31].
PCV2 vaccines seem to be able to induce a humoral im-
mune response, characterized by producing NA that are
cross-protective against both predominant PCV2 geno-
types [22]. Cross-protection between PCV2a and PCV2b
has been already demonstrated in an SPF pig infection
model [32]. Studies done to map immunogenic epitopes
in the PCV2 Cap protein have also demonstrated that
there are several epitopes that are shared between PCV2
genotypes, as well as PCV1, which presents a basis for
cross-neutralization [27,30]. Recent studies suggested that
single amino acid changes within the Cap protein deter-
mined differences at the level of neutralization by mono-
clonal antibodies [30,33]. These results further support the
evidence for antigenic variability. However, these studies
describing antigenic variation have been done using
monoclonal antibodies, which are specific for unique epi-
topes. Therefore, the objective of the present study was to
expand previous works on PCV2 antibody neutralization
by using a panel of polyclonal sera obtained from field
studies to assess the level of cross-neutralization amongst
different strains of PCV2, including both predominant ge-
notypes from two different geographical regions (Europe
and North-America).
Materials and methods
Cells
PCV1 and PCV2 negative PK-15 cells were grown in
complete Dulbecco’s Modified Eagle Medium (DMEM),which was supplemented with 10% foetal bovine serum
(FBS), PenStrep and L-glutamine (complete DMEM).
Viruses
The PCV2 isolates used in this study were propagated in
PCV-free PK-15 cells. Two isolates corresponded to geno-
type PCV2a: Burgos390L4 and Stoon-1010 strains were
isolated from pigs in Spain and Canada [22], respectively.
The other two were PCV2b genotype: MO/S-06 and
L-33-Sp-10-54 strains isolated from pigs in United States
[22] and Spain [34], respectively. In all cases, viruses were
retrieved from lymph nodes of PCV2-SD affected pigs.
Orf2/Cap sequence analysis and alignment
The complete orf2 gene from each of the four PCV2 iso-
lates used in the study was amplified and sequenced for
sequence alignment and comparison using a previously
described protocol [35]. Briefly, DNA was extracted from
viral stocks using the QIAamp DNA Mini kit (Qiagen) ac-
cording to manufacturer’s protocol. Resulting DNA was
eluted in DNase, RNase free water. The PCV2 genome
was amplified from each sample using two sets of PCR
primers [35], and the PCR products were visualized on an
agarose gel, followed by PCR product purification using
the Geneclean Kit (Bio101). Both DNA strands were se-
quenced using sequencing primers and the automated
ABI DNA Sequencer (Applied Biosystems). Percentages of
nucleotide identities and sequence alignments were done
using the Clone Manager 7 sequence analysis software
(SciEd Central) and BioEdit Sequence Alignment Editor.
Sera
Sera from twenty PCV2-SD affected animals aged between
11 and 21 weeks and seventeen age-matched healthy ani-
mals, coming both from six different Spanish PCV2-SD af-
fected farms [36], collected during the years 2005–2006,
were used in the study. In addition, 45 serum samples taken
from animals at the time of slaughter, originating from nine
additional farms without previously known clinical history,
were also included in the study. The slaughterhouse sera
were randomly selected from a serum sampling of healthy
slaughter-age pigs in Spain in 2007 [37]. All sera came from
non-PCV2 vaccinated pigs.
Immunoperoxidase monolayer assay (IPMA)
The total PCV2-specific antibody titre in each serum was
determined by immunoperoxidase monolayer assay (IPMA)
using each of the four studied viruses strains as described
previously [38]. Briefly, for each serum sample, sets of four
fold dilutions were made (from 1:20 to 1:20 480) using
complete DMEM in fixed 96 well plates containing PK-15
cells infected with one of the four tested viruses (L-33-
Sp-10-54, MO/S-06, Burgos390L4 and Stoon-1010). The
fixed cells were incubated with the diluted serum for 1 h at
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0.05% Tween 20 (PBS Tw). To each well, 50 μL of protein
A conjugated horseradish peroxidase (HRP) (Sigma) was
added to a final concentration of 0.6 μg/mL in PBS Tween
20 (Tw), and the plates were incubated for a further 1 h at
37 °C. Finally, the plates were washed with PBS Tw, and
the HRP substrate solution of 3-amino-9-diethyl carbazole
in 0.1 M acetate buffer with 0.05% hydrogen peroxide was
added at 50 μL/well to reveal the reaction.Virus Neutralization Assay (VNA)
All sera samples were tested for their ability to neutralize
each of the four test viruses (Stoon-1010, L-33-Sp-10-54,
Burgos390L4, MO/S-06), in an in vitro cross neutralization
assay. The cross neutralization assay was performed as de-
scribed previously [21], with some modifications. Briefly,
50 μL of each, non-inactivated test serum was added to the
first well in a row of a 96-well plate. The serum was diluted
two-fold in from 1:2 to 1:4096 in the 96-well plate using
complete DMEM. Each serum was tested in duplicate for
each virus. Each PCV2 isolate was diluted in complete
DMEM to obtain approximately 200 TCID50/well, and
50 μL of this dilution was added to each well of the 96-well
plate. The plates were incubated at 37 °C for 1 h. After in-
cubation, 2 × 104 freshly trypsinized PK15 cells in a 100 μL
total volume were added to each well of the 96-well plate.
The wells were mixed by pipetting, and the plates were in-
cubated for 72 h at 37 °C with 5% CO2. Each 96-well plate
also contained a negative control row containing no serum,
and a positive control row containing an antibody with
known NA titre. After 72 h, the supernatant was removed,
the wells washed one time with PBS containing 0.05%
Tween 20, and the plates were fixed by the addition of cold
absolute ethanol, and stored at −20 °C. The rest of the pro-
cedure was equivalent to that indicated for the IPMA tech-
nique, as described above. The viral inoculum used for
each assay was titrated to determine the accuracy of the
viral concentration. For each well, the number of posi-
tive cells was enumerated using a microscope at 100×
by counting those cells which displayed nuclear, cyto-
plasmic, or nuclear and cytoplasmic staining. Three
fields from each well were examined. The percentage of
virus neutralization (%VN) at each serum dilution was
calculated using the following formula: %VN [1−
(mean # of positive cells of the two replicas of each
serum dilution/mean # of positive cells in the negative
control wells)] × 100. The plates were also validated as
described previously [21]. When the plates had been
validated, the NA titre was calculated as the reciprocal
of the last dilution for which a given serum sample was
able to reduce the number of PCV2 infected cells by
50%. This value was designated as VNT50, and was re-
ported as the neutralizing titre.Statistics
The total PCV2 IPMA antibody titres were codified from
0 to 6 using the four fold dilutions (from 1:20 to 1:20 480);
i.e. an undiluted sample was codified as 0, a dilution factor
of 1:20 was codified as 1, and so on. The virus neutralizing
titres were directly used taking values from 0 (< 2) to 12
(> 4096). For every animal, four factors were considered:
sample origin (Healthy, PCV2-SD or Slaughterhouse),
PCV2 genotype (PCV2b or PCV2a), geographic origin of
the virus strain (Europe or North-America) and each par-
ticular virus strain (L-33-Sp-10-54, MO/S-06, Burgos390L4
and Stoon-1010).
In order to determine the normality of the IPMA and
VNA datasets, the Kolmogorov-Smirnov and the Shapiro-
Wilk statistics were computed for every combination of
factor and dataset (i.e. IPMA and Healthy animals). For
those datasets that gave non-significant results (data fol-
lowing normality), the corresponding parametric analysis
(1-factor ANOVA) was applied to test the existence of sig-
nificant results between the different groups included in
each factor. Conversely, the datasets that gave significant
results in the normality tests (data not following normality),
the corresponding non-parametric tests were computed:
MannWhitney’s U (one factor with two treatments) or Krus-
kal Wallis test (1 factor with more than two treatments).
Finally, the lineal correlation for every combination of
treatment and factor between IPMA and VNA was also
computed.
Results
Cap gene sequences and predicted amino acid sequences
A pairwise alignment comparing cap gene from each of
the used viruses, at both the nucleic acid and amino acid
levels was performed, the results of which are presented in
Table 1. All the four viruses had a high identity at both nu-
cleic and amino acid levels. Higher identity was observed
between L-33-Sp-10-54 and MO/S-06 (% nucleic acid/
amino acid identity: 99/99) followed between Burgos390L4
and Stoon-1010 (96/97), the first two belonging to genotype
PCV2b and the last two to genotype PCV2a. Besides,
higher divergences were observed when comparing strains
belonging to different genotypes (92-93/90-92).
The alignment of the PCV2 Cap amino acid sequences
is displayed in Figure 1. Small number of amino acid dif-
ferences occurred throughout the length of the protein,
which are highlighted by shaded boxes (Figure 1). A total
of 20 different amino acid positions showed differences
amongst the studied strains. Fourteen out of these 20 posi-
tions showed differences only when comparing the strains
belonging to different genotypes.
IPMA and VNA
The neutralizing titres for each serum sample against
each virus are presented in Table 2 (PCV2-SD and age-
Table 1 Pairwise nucleic acid/amino acid sequence comparisons for the PCV2 capsid gene
Strain Burgos390L4 (Genotype a) Stoon-1010 (Genotype a) L-33-Sp-10-54 (Genotype b) MO/S-06 (Genotype b)
Burgos390L4 (Genotype a) - 96/97 93/90 93/91
Stoon-1010 (Genotype a) 96/97 - 92/92 92/92
L-33-Sp-10-54 (Genotype b) 93/90 92/92 - 99/99
MO/S-06 (Genotype b) 93/91 92/92 99/99 -
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mals). Seventy-nine out of the 82 studied sera including
PCV2-SD affected animals, age-matched healthy counter-
parts, as well as slaughterhouse pigs, had titres of total
(IPMA) and NA against all the four tested viruses. Only the
serum of one animal, being a PCV2-SD-affected pig (refer-
ence number 9–51), had no PCV2 antibodies. Sera from
two healthy pigs (reference numbers 8–48 and 10–41) con-
tained NA against only 1 and 3 out of the 4 tested viruses,
respectively.
Results of the statistical analyses are summarized in
Figure 2. Strong to very-strong correlations between
IPMA titre and NA titre of the serum were detected in all
the studied levels (r ranging from 0.67 to 0.96). However,
IPMA and VNA gave different results. Thus, while VNA
detected significant differences stemming from sample
origin, the PCV2 genotype, and the virus strain used, the
IPMA only detected significant differences in the sample
origin. Both IPMA and VNA showed significantly lower
antibody titres in PCV2-SD-affected pigs than in their
age-matched healthy counterparts and slaughterhouse pigs
(mean total PCV2-antibodies titres and neutralizing titres
for healthy, PCV2-SD and slaughterhouse animals were
5.21, 4.38, 5.69 and 7.53, 5.80 and 8.17, respectively, P <
0.001). Globally, sera from naturally infected pigs showed
significantly higher NA titres against PCV2a genotypeFigure 1 PCV2 capsid amino acid sequence alignment of the four PCV
that differ from the genotype PCV2a Stoon-1010 strain are highlighted in gviruses than against the PCV2b genotype (mean neutraliz-
ing titres for PCV2b and PCV2a were 6.12 and 8.44, re-
spectively, P < 0.001). When analysing the specific virus
strain, Burgos390L4 and Stoon-1010 (both belonging to
genotype a) were better neutralized than L-33-Sp-10-54
and MO/S-6 (both belonging to genotype b) (P < 0.001).
Finally, no statistical differences were found either in total
antibody titre or in NA titres comparing viruses of different
geographical origin (P = 0.495 and P = 0.258, respectively).
Discussion
The present study attempted to investigate the role that
sequence variability amongst PCV2 isolates from differ-
ent origins and genotypes may play in their ability to be
neutralized, giving a further role for antigenic variation
in the immune response to PCV2. While there is a high
degree of genomic similarity among the PCV2 isolates,
as determined in this study and in previous ones [39],
monoclonal antibodies have suggested the existence of
antigenic differences within PCV2 that yield significant
neutralization differences [25-27,30]. In a natural in-
fection scenario, however, the situation is further more
complex, since there are antibodies generated against
multiple viral epitopes. Therefore, the present study
sought to examine the presence of cross-neutralizing
antibodies in the context of a natural infection. Sera2 isolates used for the cross-neutralization study. The residues
rey and black.
Table 2 Neutralizing and IPMA titres for each PCV2-SD and age-matched healthy pig serum samples against each
studied virus
Identification data Neutralizing titers IPMA (Log2)
Genotype b Genotype a Genotype b Genotype a
Farm Piglet Classification L-33-Sp-
10-54 (EU)
MO/S-06
(NA)
Burgos390L4
(EU)
Stoon-1010
(NA)
L-33-Sp-10-
54 (EU)
MO/S-06
(NA)
Burgos390L4
(EU)
Stoon-1010
(NA)
4 10 Healthy 128 256 > 4096 512 14.32 14.32 14.32 14.32
4 71 Healthy 2048 128 1024 2048 14.32 14.32 14.32 14.32
4 45 Healthy 256 32 512 > 4096 14.32 14.32 10.32 14.32
4 62 Healthy 128 128 256 2048 14.32 14.32 14.32 12.32
6 7 Healthy 512 128 64 256 14.32 14.32 12.32 14.32
6 5 Healthy 32 64 64 32 8.32 6.32 4.32 6.32
6 93 Healthy 1024 256 64 512 14.32 14.32 14.32 14.32
8 48 Healthy < 2 < 2 1024 < 2 14.32 14.32 14.32 14.32
8 42 Healthy 1024 256 512 2048 14.32 14.32 14.32 14.32
8 55 Healthy 64 256 2048 128 14.32 14.32 14.32 14.32
8 36 Healthy 512 128 1024 1024 14.32 14.32 14.32 14.32
9 3 Healthy 128 256 128 1048 14.32 14.32 14.32 14.32
9 9 Healthy 128 32 64 > 4096 14.32 14.32 14.32 14.32
9 20 Healthy 128 128 1024 1024 14.32 14.32 14.32 14.32
9 85 Healthy 128 128 1024 > 4096 14.32 14.32 14.32 14.32
10 41 Healthy < 2 4 8 8 8.32 6.32 4.32 6.32
11 31 Healthy 8 4 8 8 10.32 6.32 6.32 6.32
4 75 PCV2-SD 128 32 16 64 8.32 6.32 6.32 6.32
4 64 PCV2-SD 32 16 16 3 14.32 14.32 14.32 14.32
6 36 PCV2-SD > 4096 32 1024 256 14.32 10.32 10.32 10.32
6 14 PCV2-SD 32 26 16 3 8.32 6.32 6.32 6.32
6 64 PCV2-SD 256 64 512 28 14.32 14.32 12.32 14.32
8 90 PCV2-SD 64 8 16 4 12.32 10.32 10.32 10.32
8 82 PCV2-SD 128 128 1024 1024 14.32 14.32 14.32 14.32
9 4 PCV2-SD 4 8 16 4 10.32 8.32 6.32 6.32
9 18 PCV2-SD 16 32 1024 32 8.32 8.32 8.32 6.32
9 51 PCV2-SD < 2 < 2 < 2 < 2 0 0 0 0
9 33 PCV2-SD 8 4 8 32 14.32 14.32 12.32 12.32
10 54 PCV2-SD 32 128 256 64 14.32 14.32 12.32 12.32
10 61 PCV2-SD 64 256 64 32 14.32 10.32 10.32 12.32
10 53 PCV2-SD 32 32 64 32 14.32 14.32 8.32 8.32
10 20 PCV2-SD 64 > 4096 64 128 14.32 14.32 12.32 12.32
10 93 PCV2-SD 256 128 1024 > 4096 14.32 14.32 10.32 14.32
11 63 PCV2-SD 64 128 1024 128 14.32 14.32 14.32 14.32
11 44 PCV2-SD 4 16 8 8 6.32 6.32 4.32 4.32
11 46 PCV2-SD 512 128 64 64 14.32 12.32 12.32 10.32
11 47 PCV2-SD 64 256 256 256 14.32 14.32 14.32 14.32
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health status (PCV2-SD and age-matched healthy pigs
and a set of slaughter-aged animals) were assayed forneutralizing activity against PCV2 isolates from both
predominant genotypes and of differing geographic
origins.
Table 3 Neutralizing and IPMA titres for each slaughterhouse pig serum samples against each studied virus
Identification data Neutralization titres IPMA titres (Log2)
Genotype b Genotype a Genotype b Genotype a
Farm/pig L-33-Sp-10-54
(EU)
MO/S-06
(NA)
Burgos390L4
(EU)
Stoon-1010
(NA)
L-33-Sp-10-54
(EU)
MO/S-06
(NA)
Burgos390L4
(EU)
Stoon-1010
(NA)
A/1 128 16 > 4096 512 14.32 14.32 14.32 14.32
A/2 256 256 > 4096 2048 14.32 14.32 14.32 14.32
A/3 > 4096 128 > 4096 2048 14.32 14.32 12.32 12.32
A/4 > 4096 128 > 4096 > 4096 14.32 14.32 14.32 12.32
A/5 512 128 > 4096 > 4096 14.32 14.32 14.32 12.32
A/6 512 128 > 4096 > 4096 14.32 14.32 14.32 14.32
G2/A1 16 32 256 128 10.32 12.32 12.32 14.32
G2/A2 16 16 512 512 12.32 14.32 14.32 14.32
G2/A3 16 32 256 512 10.32 10.32 14.32 12.32
G2/A4 64 64 128 > 4096 12.32 10.32 12.32 14.32
G2/A5 32 64 64 > 4096 10.32 10.32 12.32 10.32
G9/A1 32 16 128 > 4096 8.32 8.32 8.32 10.32
G9/A2 128 32 256 > 4096 14.32 12.32 14.32 14.32
G9/A3 256 64 1024 > 4096 14.32 14.32 14.32 14.32
G9/A4 64 32 256 256 14.32 14.32 14.32 14.32
G9/A5 16 16 128 256 14.32 12.32 14.32 12.32
G16/A1 128 16 256 128 14.32 12.32 12.32 12.32
G16/A2 32 64 256 128 14.32 10.32 10.32 10.32
G16/A3 1024 32 256 256 14.32 10.32 14.32 14.32
G16/A4 1024 32 256 256 14.32 12.32 14.32 12.32
G16/A5 1024 32 512 256 12.32 8.32 8.32 8.32
G25/A1 256 32 2048 > 4096 14.32 14.32 14.32 14.32
G25/A2 256 32 2048 > 4096 14.32 14.32 14.32 14.32
G25/A3 256 512 > 4096 > 4096 14.32 14.32 14.32 14.32
G25/A4 256 128 256 128 14.32 14.32 12.32 14.32
G25/A5 256 > 4096 256 128 14.32 14.32 12.32 12.32
G27/A1 1024 32 256 128 14.32 14.32 12.32 14.32
G27/A2 32 16 32 > 4096 14.32 14.32 14.32 14.32
G27/A3 32 32 32 > 4096 14.32 14.32 14.32 14.32
G27/A5 64 64 256 2048 14.32 14.32 12.32 12.32
G49/A1 128 64 256 > 4096 14.32 14.32 14.32 14.32
G49/A2 256 512 1024 > 4096 14.32 14.32 14.32 14.32
G49/A3 1024 128 128 1024 14.32 14.32 14.32 14.32
G49/A4 1024 256 128 1024 14.32 14.32 14.32 14.32
G49/A5 1024 128 128 512 14.32 14.32 14.32 14.32
G73/A1 128 64 2048 512 14.32 14.32 14.32 14.32
G73/A2 128 32 2048 512 14.32 14.32 14.32 14.32
G73/A3 128 32 1024 256 14.32 14.32 14.32 14.32
G73/A4 2048 512 512 1024 14.32 14.32 14.32 14.32
G73/A5 > 4096 > 4096 512 1024 14.32 14.32 14.32 14.32
G87/A1 64 32 1024 512 14.32 14.32 12.32 10.32
G87/A2 64 32 2048 512 14.32 14.32 14.32 14.32
G87/A3 64 64 2048 256 14.32 14.32 14.32 14.32
G87/A4 64 64 > 4096 512 14.32 14.32 14.32 14.32
G87/A5 128 512 > 4096 512 14.32 14.32 14.32 14.32
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Immunoperoxidase monolayer
(IPMA)
Sample Origin
1.- Healthy
 (r=0.86)
2.- PCV2-SD
 (r=0.67)
3.- Slaughterhouse
 (r=0.96)
PCV2 genotype
1.- PCV2b
 (r=0.77)
2.- PCV2a
 (r=0.91)
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 (r=0.91)
2.- North-America
 (r=0.88)
Virus within the test
1.- L-33-Sp-10-54
 (PCV2b) (r=0.83)
2.- MO/S-06
 (PCV2b) (r=0.68)
3.- Burgos390L4
 (PCV2a) (r=0.96)
4.- Stoon-1010
 (PCV2a) (r=0.87)
Kruskal Wallis test
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1-factor ANOVA
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Mann-Whitney's U 
sign. (P<0.001)
Student's t 
n.s. (P=0.084)
Mann-Whitney's U
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Student's t 
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tained NA able to neutralize all four studied viral strains.
Moreover, there was a significant positive correlation be-
tween total antibody titres and NA titres, which is in agree-
ment with previous works [21,22]. Both IPMA and VNA
showed lower titres of antibodies in PCV2-SD-affected pigs
compared to their age-matched healthy counterparts and
to slaughterhouse pigs. This is also in agreement with pre-
vious works [20,21] and supports the notion that PCV2-
SD-affected pigs develop an impaired humoral response
against PCV2.
A salient feature was that IPMA and VNA displayed
different results when compared to the used virus strain and
the genotype. Thus, meanwhile total antibody titres mea-
sured by means of IPMA in the studied sera did not show
differences in this regards, higher NA titres were detected
against PCV2a isolates than against PCV2b ones. Accord-
ingly, studied sera were able to neutralize Burgos390L4 andStoon-1010 strains (PCV2a) better than L-33-Sp-10-54 and
MO/S-06 strains (PCV2b). These results support the hy-
pothesis that there is a difference in the antigenic properties
of these viruses [26-28,30,33], results that seem to be
confirmed after the sequence analysis of the 4 PCV2 isolates
used in this assay for the in vitro studies. To date, several
specific amino acid positions have been indicated as import-
ant for PCV2 neutralization: 59 [28], 131, 151, 190, 191 [33]
and the C-terminal area including residues 231–233 [27].
Looking back at the analysis of the amino acid sequence
differences among the studied viruses, it was observed that
5 out of these 6 positions (59, 131, 151, 190, and 231–233)
showed variations among the studied viruses. Among them,
positions 151,190 and 231–233 allowed discrimination of
both genotypes, while variations in positions 59 and 131
were only observed in Burgos390L4 strain (PCV2a). On one
hand, mutation of T→A at position 190 has been suggested
to cause loss of neutralization capabilities [33]. Interestingly,
Kurtz et al. Veterinary Research 2014, 45:29 Page 8 of 10
http://www.veterinaryresearch.org/content/45/1/29both strains belonging to PCV2b, which were less effectively
neutralized, contained A at position 190, while both PCV2a
strains had S in this position. In the same line, position 59
has been suggested to be a critical position for PCV2a sero-
neutralization, and the change from A to R was indicated to
cause loss of the neutralizing capacity [28]. Amongst the
studied strains, this change was observed in both strains
belonging to PCV2b, as well as in Stoon-1010 (PCV2a). In
addition, Saha et al. also indicated that mutations the change
of P→T at position 151 resulted in an increase of
neutralization [33]. This is in contrast with the present
results, in which amino acids P and T were present in
PCV2a and PCV2b, respectively. Finally, Saha et al. also
suggested that a mutation of T→ P in position 131 reduced
neutralization, while all the here presented strains except
Burgos390L4 contained a T in this position [33]. Taken
together, results of the present study support the idea that
described amino acid positions may have importance in
PCV2 seroneutralization capacity. However, results also
point towards the idea that there is no a single epitope
responsible for the susceptibility of the different PCV2 strain
to seroneutralization. Likely, the overall neutralization cap-
ability of a serum depends on the balance between existing
antibodies against the different neutralizing epitopes.
The group of serum samples coming from PCV2-SD
affected farms was previously included in a sequencing
study which showed that, in these farms, the vast majority
of recovered PCV2 sequences belonged to PCV2b genotype
[40]. Besides, attempts to sequencing PCV2 from the serum
samples coming from the slaughterhouse were not per-
formed, since it is unlikely to detect the presence of PCV2
at this age [41,42]. Nevertheless, similarly to what was
observed in our PCV2-SD affected farms [40], several field
studies have demonstrated that PCV2b genotype is cur-
rently predominant in the field [12,14,43]. Moreover, those
studies have described a shift of infection prevalence from
PCV2a to PCV2b [12,14,43]. The here observed lower abil-
ity of the field serum samples to neutralize viruses belong-
ing to PCV2b than PCV2a might have facilitated the spread
of the first over the second, which could have facilitated the
occurrence of the reported shift. The reasons why sera
coming from pigs with predominance of PCV2b infection
showed lower ability to neutralize in vitro viruses belonging
to PCV2b than PCV2a could not be determined in this
study. It cannot be ruled out that PCV2a circulated also
among the studied pigs. Hypothetical PCV2a circulation at
earlier ages and/or a lower PCV2a loads than those of
PCV2b might have caused the lack (or minimal) of PCV2a
detection. The study of serum samples coming from experi-
mental infections with PCV2a, PCV2b and PCV2a/PCV2b
should help in clarifying these hypotheses.
Present data also showed no differences between capacity
of seroneutralization of viruses of different geographic
origin (Europe and North America), highlighting that viralgenetic differences but not their geographic origin may
determine different magnitudes of humoral response [22].
Further neutralization studies including other PCV2 strains
belonging to different genogroups within genotypes should
contribute to understand the role of PCV2 genetic variation
with the capacity of generation of NA.
Of particular importance is how these antigenic differ-
ences may relate to the production of a vaccine that would
protect against all PCV2 isolates. Cross-protection between
PCV2 genotypes has been demonstrated experimentally
[22,32] and is further supported by the efficacy of PCV2a-
based vaccines under field [8] and experimental [22] condi-
tions. Nevertheless, a recent experimental study indicated
that a PCV2 vaccine based on genotype 2b was more effect-
ive in protecting pigs against the effects of PCV2b or con-
current PCV2a–PCV2b challenge compared to a vaccine
based on the PCV2a genotype [44]. Since protection against
PCV2 is known to be dependent on the generation of NA
[20,21], presented data showing differential ability of sera to
neutralize viruses of different genotypes may explain the
hypothesis that PCV2a vaccines might be less effective in
reducing the prevalence of PCV2b than PCV2a [44]. The
present study suggests that, in the next future, may be
worthwhile to attempt to create vaccines that more specific-
ally target the PCV2b and/or PCV2b/PCV2a antigenic
epitopes to boost the degree of vaccine efficacy across all
genotypes.
In summary, results of the present work suggests that
sequence differences between PCV2 isolates translate to
functional antigenic differences in viral neutralization
in vivo, which are related to the virus genotype but not with
its potential geographic origin.
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